| London Stock Exchange: VAL
ValiRx Plc is a biopharmaceutical company. It is engaged in the business developing novel technologies and products in oncology therapeutics and diagnostics. The company's product focuses on the epigenomic analysis and treatment of cancer, as well as the technologies can be also applied in other fields, such as neurology and inflammatory diseases. It operates through the following divisions: ValiPharma, ValiFinn and ValiMedix. The ValiPharma division focuses on developing personalised medicines to bring more advanced therapeutic options for the treatment of cancer. The ValiFinn division engages in biomarkers and diagnostic development. The ValiMedix division provides sales and distribution services. The company's segments include Drug Development and the Sale of Self-Test Drug Kits. ValiRx was founded on June 1, 2006 and is headquartered in London, the United Kingdom.